<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC6968813\results\search\drug\results.xml">
  <result pre="of TB showing resistance to single first-line anti-TB drugs only." exact="Isoniazid" post="(H) resistance is a type of mono-DR-TB and has"/>
  <result pre="to more than one first-line anti-TB drug other than both" exact="rifampicin" post="(R) and H. RR-TB is defined as a case"/>
  <result pre="drugs â€&quot; at least one of three FQs (ofloxacin [Ofx]," exact="levofloxacin" post="[Lfx], moxifloxacin [Mfx]) or one of three SLIDs (capreomycin"/>
  <result pre="[Lfx], moxifloxacin [Mfx]) or one of three SLIDs (capreomycin [Cm]," exact="kanamycin" post="[Km], amikacin (Am)] but not to both â€&quot; also"/>
  <result pre="[Mfx]) or one of three SLIDs (capreomycin [Cm], kanamycin [Km]," exact="amikacin" post="(Am)] but not to both â€&quot; also known as"/>
  <result pre="state; drug malabsorption of anti-TB drugs, such as R and" exact="ethambutol" post="(E), leading to drug resistance and treatment failure; early"/>
  <result pre="1â€&quot;2 days. Resistance can be detected by WGS for even" exact="bedaquiline" post="(Bdq) and delamanid (Dlm) lacking validated DST. However, there"/>
  <result pre="can be detected by WGS for even bedaquiline (Bdq) and" exact="delamanid" post="(Dlm) lacking validated DST. However, there are various concerns"/>
  <result pre="smear) with Km, gatifloxacin (Gfx) or Mfx, prothionamide (Pto)/ethionamide (Eto)," exact="clofazimine" post="(Cfz), high-dose H, Z, and E followed by a"/>
  <result pre="evidence regarding treatment outcome and profile of ADRs, especially with" exact="linezolid" post="(Lzd), Cfz, Bdq, and Dlm.1 The conventional regimen contains"/>
  <result pre="a regimen to achieve better outcomes. High-dose H, Gfx, and" exact="clarithromycin" post="(Clr) have been omitted from a recent classification, because"/>
  <result pre="for treatment of HIV Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors" exact="Zidovudine" post="(Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl);"/>
  <result pre="of HIV Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors Zidovudine (Azt/Zdv);" exact="stavudine" post="(d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC);"/>
  <result pre="Group Antiretroviral drugs Nucleoside reverse-transcriptase inhibitors Zidovudine (Azt/Zdv); stavudine (d4T);" exact="lamivudine" post="(3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC); emtricitabine (FTC)"/>
  <result pre="drugs Nucleoside reverse-transcriptase inhibitors Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC);" exact="abacavir" post="(Abc); didanosine (ddl); zalcitabine (ddC); emtricitabine (FTC) Nucleotide reverse-transcriptase"/>
  <result pre="reverse-transcriptase inhibitors Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc);" exact="didanosine" post="(ddl); zalcitabine (ddC); emtricitabine (FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir"/>
  <result pre="Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl);" exact="zalcitabine" post="(ddC); emtricitabine (FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside"/>
  <result pre="stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC);" exact="emtricitabine" post="(FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors"/>
  <result pre="emtricitabine (FTC) Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors" exact="Nevirapine" post="(Nvp); efavirenz (Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv)"/>
  <result pre="Nucleotide reverse-transcriptase inhibitors Tenofovir (TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors Nevirapine (Nvp);" exact="efavirenz" post="(Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors"/>
  <result pre="(TDF) Nonâ€&quot;nucleoside reverse-transcriptase inhibitors Nevirapine (Nvp); efavirenz (Efv); delavirdine (Dlv);" exact="rilpivirine" post="(Rpv); eltravirine (Etv) Protease inhibitors Saquinavir (Sqv); ritonavir (Rtv);"/>
  <result pre="efavirenz (Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors" exact="Saquinavir" post="(Sqv); ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv);"/>
  <result pre="delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors Saquinavir (Sqv);" exact="ritonavir" post="(Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv);"/>
  <result pre="rilpivirine (Rpv); eltravirine (Etv) Protease inhibitors Saquinavir (Sqv); ritonavir (Rtv);" exact="nelfinavir" post="(Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv);"/>
  <result pre="eltravirine (Etv) Protease inhibitors Saquinavir (Sqv); ritonavir (Rtv); nelfinavir (Nfv);" exact="amprenavir" post="(Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv); atazanavir (Atv);"/>
  <result pre="Saquinavir (Sqv); ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv);" exact="lopinavir" post="(Lpv); fosamprenavir (Fpv); atazanavir (Atv); tipranavir (Tpv); darunavir (Drv)"/>
  <result pre="ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv);" exact="fosamprenavir" post="(Fpv); atazanavir (Atv); tipranavir (Tpv); darunavir (Drv) Integrase strandâ€&quot;transferase"/>
  <result pre="nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv);" exact="atazanavir" post="(Atv); tipranavir (Tpv); darunavir (Drv) Integrase strandâ€&quot;transferase inhibitors Raltegravir"/>
  <result pre="amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv); atazanavir (Atv);" exact="tipranavir" post="(Tpv); darunavir (Drv) Integrase strandâ€&quot;transferase inhibitors Raltegravir (Rgv); elvitegravir"/>
  <result pre="established coinfection Regimens for DR-TB component Regimens for HIV component" exact="Isoniazid" post="(H) mono/polydrug resistanceWHO 2016 IP (3â€&quot;6 months): Lfx +"/>
  <result pre="cases of H-monoresistant or poly-DR-TB: R to be substituted with" exact="rifabutin" post="or rifapentine if patient is on PI or integrase"/>
  <result pre="or integrase inhibitors. The currently approved regimen includes tenofovir (TDF)," exact="lamivudine" post="(3TC), and efavirenz (Efv)/nevirapine (Nvp) or dolutegravir (Dtg), if"/>
  <result pre="The currently approved regimen includes tenofovir (TDF), lamivudine (3TC), and" exact="efavirenz" post="(Efv)/nevirapine (Nvp) or dolutegravir (Dtg), if available. Second-line regimens"/>
  <result pre="recommended second-line regimens for adults include two NRTIs, such as" exact="zidovudine" post="(Azt) with 3TC, and a boosted protease inhibitor (PI),"/>
  <result pre="drugs. NRTIs, PIs, integrase strandâ€&quot;transferase inhibitors, and the CCR5 antagonist" exact="maraviroc" post="are more prone to interactions with R than NRTIs,"/>
  <result pre="by CYP3A4 and have weak inhibitory activity. Of all PIs," exact="ritonavir" post="has a potent inhibitory effect on CYP3A4 and Pgp."/>
  <result pre="mono-DR-TB. Relevant drugâ€&quot;drug interactions are described in Table 4. Buffered" exact="didanosine" post="(ddl), which contains an aluminum magnesiumâ€&quot;based antacid, may result"/>
  <result pre="(inhibitor) Pgp/BCRP/MRP1 R (inducer); Cfz (inhibitor) All PIs; Efv; Nvp;" exact="maraviroc" post="Uridine 5Ê¹-diphospho-glucuronosyltransferase (UGT) R (inducer); Cfz (inducer); Clr (inducer);"/>
  <result pre="neuropathy associated primarily with either HIV infection or combination with" exact="stavudine" post="(d4T) and also bone-marrow depression when coadministered with Azt."/>
  <result pre="(D4T, ddI, or ddC) in future.â—� Also consider gallstones or" exact="alcohol" post="as a potential cause of pancreatitis Diarrhea All protease"/>
  <result pre="Hepatotoxicity Nvp, Efv, all PIs, all NsRTIs, all integrase inhibitors," exact="maraviroc" post="H, R, E, Z, PAS, Eto/Pto, Ofx, Lfx, Mfx,"/>
  <result pre="B, C, and CMV) Skin rash Abc, Nvp, Efv, D4T," exact="maraviroc" post="H, R, Z, PAS, Am, Km, Ofx, Lfx, Mfx,"/>
  <result pre="â—� Clinical correlation to rule out offending drugâ—� Monitoring with" exact="creatine" post="phosphokinaseâ—� Thorough clinical evaluation to rule out HIV-associated myopathyâ—�"/>
  <result pre="on three components known as the â€œthree Isâ€�: intensified case-finding," exact="isoniazid" post="preventive therapy, and infection control. The Joint United Nations"/>
  <result pre="both first- and second-line anti-TB drugs, and DST-tailored individualized treatment." exact="Prompt" post="initiation of appropriate anti-TB regimens tailored to DST results"/>
  <result pre="for diagnosis of drug-resistant tuberculosis in people living with HIV." exact="Prompt" post="Introduction of ART in M/XDR-TB/HIV Patients as Soon as"/>
  <result pre="often infected with the same strain as the index case." exact="Prompt" post="treatment of the index case with DR-TB should be"/>
  <result pre="suspected and investigated further with the CBNAAT or appropriate investigation." exact="Prompt" post="initiation of treatment with a regimen designed to treat"/>
  <result pre="14.LawnSD, BrooksSV, KranzerK, et al. Screening for HIV-associated tuberculosis and" exact="rifampicin" post="resistance before antiretroviral therapy using the xpert MTB/RIF assay:"/>
  <result pre="amplification technology for rapid and simultaneous detection of tuberculosis and" exact="rifampicin" post="resistance: xpert MTB/RIF assay for the diagnosis of pulmonary"/>
  <result pre="al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and" exact="rifampicin" post="resistance: a prospective multi-centre diagnostic accuracy study. Lancet Infect"/>
  <result pre="2008;198(7):948â€&quot;961. doi:10.1086/59145918713054 63.SemvuaHH, KibikiGS, KisangaER, et al. Pharmacological interactions between" exact="rifampicin" post="and antiretroviral drugs: challenges and research priorities for resource-limited"/>
  <result pre="2015;37:22â€&quot;32. doi:10.1097/FTD.000000000000010824943062 64.Oâ€™DonnellMR, PadayatchiN, DaftaryA, et al. Antiretroviral switching and" exact="bedaquiline" post="treatment of drug-resistant tuberculosis HIV co-infection. Lancet HIV. 2019;6(3):e201â€&quot;e204."/>
  <result pre="co-infection. Lancet HIV. 2019;6(3):e201â€&quot;e204. doi:10.1016/S2352-3018(19)30035-930846058 65.MallikaarjunS, WellsC, PetersenC, et al." exact="Delamanid" post="co-administered with antiretroviral drugs or anti-tuberculosis drugs shows no"/>
  <result pre="SaraceniV, MoultonLH, et al. Effect of improved tuberculosis screening and" exact="isoniazid" post="preventive therapy on incidence of tuberculosis and death in"/>
  <result pre="trial. Lancet Infect Dis. 2013;13(10):852â€&quot;858. doi:10.1016/S1473-3099(13)70187-723954450 100.AyeleHT, MourikMS, DebrayTP, BontenMJ." exact="Isoniazid" post="prophylactic therapy for the prevention of tuberculosis in HIV"/>
 </snippets>
</snippetsTree>
